Differential characteristics of incobotulinumtoxinA and its use in the management of glabellar frown lines

References

• FlynnTCCarruthersACarruthersJValidated assessment scales for the upper faceDermatol Surg2012382 Spec30931922316187
   PubMed Web of Science ®Google Scholar
• FriedmanOChanges associated with the aging faceFacial Plast Surg Clin North Am200513337138016085282
   PubMedGoogle Scholar
• FedokFGThe aging faceFacial Plast Surg19961221071159220725
   PubMedGoogle Scholar
• CoxSEFinnJCSocial implications of hyperdynamic facial lines and patient satisfaction outcomesInt Ophthalmol Clin2005453132415970763
   PubMedGoogle Scholar
• CarruthersAKieneKCarruthersJBotulinum A exotoxin use in clinical dermatologyJ Am Acad Dermatol1996345 Pt 17887978632076
   PubMed Web of Science ®Google Scholar
• CarruthersJALoweNJMenterMAA multicenter, doubleblind, randomized, placebo-controlled study of the efficacy and safety of botulinum toxin type A in the treatment of glabellar linesJ Am Acad Dermatol200246684084912063480
   PubMed Web of Science ®Google Scholar
• WollmerMAde BoerCKalakNFacing depression with botulinum toxin: a randomized controlled trialJ Psychiatr Res201246557458122364892
   PubMed Web of Science ®Google Scholar
• SasakiGHComparison of results of wire subcision performed alone, with fills, and/or with adjacent surgical proceduresAesthet Surg J200828661962619083589
   PubMedGoogle Scholar
• De CordierBCde la TorreJIAl-HakeemMSEndoscopic forehead lift: review of technique, cases, and complicationsPlast Reconstr Surg2002110615581568 discussion 1569–157012409778
   PubMed Web of Science ®Google Scholar
• HafeziFNaghibzadehBNouhiANaghibzadehGEliminating frown lines with an endoscopic forehead lift procedure (corrugator muscle disinsertion)Aesthetic Plast Surg201135451652121298513
   PubMed Web of Science ®Google Scholar
• MandelMATreatment of glabellar frown lines using silicone implantsAnn Plast Surg19912721101141952732
   PubMed Web of Science ®Google Scholar
• BrandtFSBellmanBCosmetic use of botulinum A exotoxin for the aging neckDermatol Surg19982411123212349834744
   PubMed Web of Science ®Google Scholar
• CarruthersJDCarruthersJATreatment of glabellar frown lines with C. botulinum-A exotoxinJ Dermatol Surg Oncol199218117211740562
   PubMedGoogle Scholar
• BlugermanGSchavelzonDAnderhuberFMartinezLChomyzsynACorrugator supercilii muscle terminal nerve ablation using a novel thread technique for the treatment of hyperdynamic vertical glabellar furrowsJ Drugs Dermatol201110776276521720658
   PubMed Web of Science ®Google Scholar
• CarruthersJDGlogauRGBlitzerAAdvances in facial rejuvenation: botulinum toxin type a, hyaluronic acid dermal fillers, and combination therapies – consensus recommendationsPlast Reconstr Surg2008121Suppl 55S30S quiz 31S–36S18449026
   PubMed Web of Science ®Google Scholar
• ChoSBLeeSJHwangYSLeeKCOhSHRadiofrequency-selective nerve ablation for glabellar frown lines in East Asian patientsClin Exp Dermatol2009347e393e39419548942
   PubMed Web of Science ®Google Scholar
• KimJHJeongJWSonDPercutaneous selective radiofrequency nerve ablation for glabellar frown linesAesthet Surg J201131774775521908806
   PubMed Web of Science ®Google Scholar
• NahaiFRUpdate on radiofrequency ablation of the frontal branch to the corrugator muscles to reduce glabellar frown linesPlast Reconstr Surg20101255208e
   Google Scholar
• DreizenNGFrammLSudden unilateral visual loss after autologous fat injection into the glabellar areaAm J Ophthalmol1989107185872912125
   PubMed Web of Science ®Google Scholar
• TeimourianBBlindness following fat injectionsPlast Reconstr Surg19888223613399569
   PubMed Web of Science ®Google Scholar
• StephanSWangTDBotulinum toxin: clinical techniques, applications, and complicationsFacial Plast Surg201127652953922205526
   PubMed Web of Science ®Google Scholar
• PragerWRapplTPhase IV study comparing incobotulinumtoxinA and onabotulinumtoxinA using a 1:1.5 dose-conversion ratio for the treatment of glabellar frown linesJ Cosmet Dermatol Epub 2012 Oct 2
   Web of Science ®Google Scholar
• BeerKRBoydCPatelRKBowenBJamesSPBrinMFRapid onset of response and patient-reported outcomes after onabotulinumtoxinA treatment of moderate-to-severe glabellar linesJ Drugs Dermatol2011101394421197522
   PubMed Web of Science ®Google Scholar
• Bocouture^®. Summary of product characteristicsFrankfurt am Main, GermanyMerz Pharmaceuticals GmbH2012
   Google Scholar
• FedokFGAdvances in minimally invasive facial rejuvenationCurr Opin Otolaryngol Head Neck Surg200816435936818626256
   PubMed Web of Science ®Google Scholar
• GoldmanAWollinaUFacial rejuvenation for middle-aged women: a combined approach with minimally invasive proceduresClin Interv Aging2010529329920924438
   PubMed Web of Science ®Google Scholar
• Azzalure^®. Summary of product characteristicsBerkshire, UKIpsen Ltd2010
   Google Scholar
• RaspaldoHBaspeyrasMBellityPUpper- and mid-face anti-aging treatment and prevention using onabotulinumtoxin A: the 2010 multidisciplinary French consensus – part 1J Cosmet Dermatol201110135021332909
   PubMed Web of Science ®Google Scholar
• Trindade De AlmeidaARSeccoLCCarruthersAHandling botulinum toxins: an updated literature reviewDermatol Surg201137111553156521777338
   PubMed Web of Science ®Google Scholar
• BakheitAMThe possible adverse effects of intramuscular botulinum toxin injections and their managementCurr Drug Saf20061327127918690938
   PubMedGoogle Scholar
• CarruthersACarruthersJCohenJDilution volume of botulinum toxin type A for the treatment of glabellar rhytides: does it matter?Dermatol Surg2007331 SpecS97S10417241422
   PubMed Web of Science ®Google Scholar
• KleinAWDilution and storage of botulinum toxinDermatol Surg19982411117911809834735
   PubMed Web of Science ®Google Scholar
• KleinAWComplications and adverse reactions with the use of botulinum toxinDis Mon200248533635612195264
   PubMed Web of Science ®Google Scholar
• FranciscoGEBotulinum toxin: dosing and dilutionAm J Phys Med Rehabil200483Suppl 10S30S3715448575
   PubMed Web of Science ®Google Scholar
• PragerWZschockeIReichCBrocattiLHenningKSteinkrausVDoes dilution have an impact on cosmetic results with BoNT/A? Complex-protein-free BoNT/A for treatment of glabella linesHautarzt2009601081582019771403
   PubMed Web of Science ®Google Scholar
• HankinsCLStrimlingRRogersGSBotulinum A toxin for glabellar wrinkles. Dose and responseDermatol Surg19982411118111839834736
   PubMed Web of Science ®Google Scholar
• Vistabel^®. Summary of product characteristicsIrvine, CAAllergan, Inc2010
   Google Scholar
• CarruthersJFagienSMatarassoSLConsensus recommendations on the use of botulinum toxin type a in facial aestheticsPlast Reconstr Surg2004114Suppl 61S22S15507786
   PubMed Web of Science ®Google Scholar
• ImhofMKühneUA Phase III study of incobotulinumtoxinA in the treatment of glabellar frown linesJ Clin Aesthet Dermatol2011410283422010053
   PubMedGoogle Scholar
• Trindade de AlmeidaARMartins da Costa MarquesERKaduncBVGlabellar wrinkles: a pilot study of contraction patternsSurg Cosmet Dermatol2010212328
   Google Scholar
• CarruthersJDLoweNJMenterMAGibsonJEadieNDouble-blind, placebo-controlled study of the safety and efficacy of botulinum toxin type A for patients with glabellar linesPlast Reconstr Surg200311241089109812973229
   PubMed Web of Science ®Google Scholar
• CarruthersACarruthersJColemanWPIIIMulticentre, randomized, Phase III study of a single dose of incobotulinumtoxinA, free from complexing proteins, in the treatment of glabellar frown linesDermatol Surg2013
   Web of Science ®Google Scholar
• HankeCWNarinsRSBrandtFA randomized, placebo-controlled, double blind Phase III trial investigating the efficacy and safety of incobotulinumtoxinA in the treatment of glabellar frown lines using a stringent composite endpointDermatol Surg2013
   Google Scholar
• RzanyBFlynnTCSchlöbeAHeinzMHarringtonLLong-term results for incobotulinumtoxinA in the treatment of glabellar frown linesDermatol Surg2013399510323190342
   PubMed Web of Science ®Google Scholar
• CarruthersACarruthersJSaidSDose-ranging study of botulinum toxin type A in the treatment of glabellar rhytids in femalesDermatol Surg200531441442215871316
   PubMed Web of Science ®Google Scholar
• GrimesPEShabazzDA four-month randomized, double-blind evaluation of the efficacy of botulinum toxin type A for the treatment of glabellar lines in women with skin types V and VIDermatol Surg2009353429435 discussion 435–42619250310
   PubMed Web of Science ®Google Scholar
• Moers-CarpiMFulford-SmithATanKA multicenter, randomized, double-blind study to evaluate the efficacy of onabotulinumtoxina (20 units) in the treatment of glabellar lines, when compared to incoboulinumtoxina (30 units)J Am Acad Dermatol201266481AB20
   Google Scholar
• SattlerGCallanderMJGrablowitzDNoninferiority of incobotulinumtoxinA, free from complexing proteins, compared with another botulinum toxin type A in the treatment of glabellar frown linesDermatol Surg201036Suppl 42146215421134045
   PubMed Web of Science ®Google Scholar
• DresslerDBeneckeRPharmacology of therapeutic botulinum toxin preparationsDisabil Rehabil200729231761176818033601
   PubMed Web of Science ®Google Scholar
• HackettRKamPCBotulinum toxin: pharmacology and clinical developments: a literature reviewMed Chem20073433334517627570
   PubMed Web of Science ®Google Scholar
• RosalesRLBigalkeHDresslerDPharmacology of botulinum toxin: differences between type A preparationsEur J Neurol200613Suppl 121016417591
   PubMed Web of Science ®Google Scholar
• DongMYehFTeppWHSV2 is the protein receptor for botulinum neurotoxin AScience2006312577359259616543415
   PubMed Web of Science ®Google Scholar
• HambletonPClostridium botulinum toxins: a general review of involvement in disease, structure, mode of action and preparation for clinical useJ Neurol1992239116201311751
   PubMed Web of Science ®Google Scholar
• JostWHBlumelJGrafeSBotulinum neurotoxin type A free of complexing proteins (XEOMIN) in focal dystoniaDrugs200767566968317385940
   PubMed Web of Science ®Google Scholar
• FrevertJDresslerDComplexing proteins in botulinum toxin type A drugs: a help or a hindrance?Biologics2010432533221209727
   PubMedGoogle Scholar
• EiseleK-HTaylorHDissociation of the 900 kDa neurotoxin complex from C.botulinum under physiological conditionsToxicon200851Suppl 110 (Abstr 28)18045635
   PubMed Web of Science ®Google Scholar
• KerscherMRollSBeckerAWigger-AlbertiWComparison of the spread of three botulinum toxin type A preparationsArch Dermatol Res2012304215516122002325
   PubMed Web of Science ®Google Scholar
• EiseleK-HFinkKVeyMTaylorHVStudies on the dissociation of botulinum neurotoxin type A complexesToxicon201157455556521195107
   PubMed Web of Science ®Google Scholar
• ChenFKuziemkoGMStevensRCBiophysical characterization of the stability of the 150-kilodalton botulinum toxin, the nontoxic component, and the 900-kilodalton botulinum toxin complex speciesInfect Immun1998666242024259596697
   PubMed Web of Science ®Google Scholar
• GreinSMGFinkKStability of botulinum neurotoxin type A, devoid of complexing proteinsThe Botulinum Journal2011214958
   Google Scholar
• FrevertJContent of botulinum neurotoxin in Botox®/Vistabel®, Dysport®/Azzalure®, and Xeomin®/Bocouture®Drugs R D2010102677320698714
   PubMedGoogle Scholar
• CarruthersACarruthersJBotulinum toxin products overviewSkin Therapy Lett20081361418806905
   PubMedGoogle Scholar
• BorodicGImmunologic resistance after repeated botulinum toxin type A Injections for facial rhytidesOphthal Plast Reconstr Surg2006223239240
   Web of Science ®Google Scholar
• DresslerDWohlfahrtKMeyer-RoggeEWiestLBigalkeHAntibody-induced failure of botulinum toxin a therapy in cosmetic indicationsDermatol Surg201036Suppl 42182218721134050
   PubMed Web of Science ®Google Scholar
• LeeS-KAntibody-induced failure of botulinum toxin type A therapy in a patient with masseteric hypertrophyDermatol Surg2007331 SpecS105S11017278332
   PubMed Web of Science ®Google Scholar
• StengelGBeeEKAntibody-induced secondary treatment failure in a patient treated with botulinum toxin type A for glabellar frown linesClin Interv Aging2011628128422162643
   PubMed Web of Science ®Google Scholar
• BlümelJFrevertJSchwaierAComparative antigenicity of three preparations on boutlinum neurotoxin A in the rabbitNeurotox Res20069238
   Google Scholar
• Jimenez-ShahedJA new treatment for focal dystonias: incobotulinumtoxinA (Xeomin®), a botulinum neurotoxin type A free from complexing proteinsNeuropsychiatr Dis Treat20128132522275842
   PubMed Web of Science ®Google Scholar
• BeneckeRXeomin in the treatment of cervical dystoniaEur J Neurol200916Suppl 261020002740
   PubMed Web of Science ®Google Scholar
• BigalkeHFrevertJBotulinum toxin A: dose and immune responseInt J Rehabil Res20123529322561214
   PubMed Web of Science ®Google Scholar
• JankovicJVuongKDAhsanJComparison of efficacy and immunogenicity of original versus current botulinum toxin in cervical dystoniaNeurology20036071186118812682332
   PubMed Web of Science ®Google Scholar
• PanjwaniNO’KeeffeRPickettABiochemical, functional and potency characteristics of type A botulinum toxin in clinical useBotulinum J200811153166
   Google Scholar
• DresslerDManderGFinkKMeasuring the potency labelling of onabotulinumtoxinA (Botox®) and incobotulinumtoxinA (Xeomin®) in an LD50 assayJ Neural Transm20121191131521971766
   PubMed Web of Science ®Google Scholar
• SattlerGCallanderMGrablowitzDNoninferiority of incobotulinumtoxinA, free from complexing proteins, compared with another botulinum toxin type A in the treatment of glabellar frown linesDermatol Surg201036S42146215421134045
   PubMed Web of Science ®Google Scholar
• de AlmeidaATDe BoulleKDiffusion characteristics of botulinum neurotoxin products and their clinical significance in cosmetic applicationsJ Cosmet Laser Ther20079Suppl 1172217885882
   PubMedGoogle Scholar
• HexselDDal’FornoTHexselCDo PradoDZLimaMMA randomized pilot study comparing the action halos of two commercial preparations of botulinum toxin type ADermatol Surg2008341525918053050
   PubMed Web of Science ®Google Scholar
• Trindade de AlmeidaARMarquesEde AlmeidaJCunhaTBorasoRPilot study comparing the diffusion of two formulations of botulinum toxin type A in patients with forehead hyperhidrosisDermatol Surg2007331 SpecS37S4317241413
   PubMed Web of Science ®Google Scholar
• SnapinnSMNoninferiority trialsCurr Control Trials Cardiovasc Med200011192111714400
   PubMedGoogle Scholar
• PintoVFNon-inferiority versus equivalence clinical trials in assessing biological productsSao Paulo Med J2011129318318421755255
   PubMed Web of Science ®Google Scholar
• RapplTWiednerMKranzlbinderBHaasFIs there a difference in persistence, efficiency and efficacy of 3 BoNT/A-containing products? A double-blind, randomised studyPresented at the International Master Course on Aging Skin Asia Congress2010Hong Kong, China
   Google Scholar
• Merz Pharmaceuticals GmbHIncobotulinumtoxinA (Xeomin) versus placebo in the treatment of glabellar frown lines http://clinicaltrials.gov/ct2/show/NCT00430963?term=NCT00430963&rank=1Accessed August 31, 2012
   Google Scholar
• Merz Pharmaceuticals GmbHFinding of optimal dose for NT 201 in the treatment of glabellar frown lines http://clinicaltrials.gov/ct2/show/NCT00430586?term=NCT00430586&rank=1Accessed August 31, 2012
   Google Scholar
• SchleyerVBerneburgMEfficacy and safety of botulinum neurotoxin type A (Xeomin) in the treatment of facial expression frown linesKosmetische Medizin – ENGLISH Abstract2008
   Google Scholar
• SchlessingerJMonheitGKaneMAMendelsohnNTime to onset of response of abobotulinumtoxina in the treatment of glabellar lines: a subset analysis of phase 3 clinical trials of a new botulinum toxin type ADermatol Surg201137101434144221745254
   PubMed Web of Science ®Google Scholar
• PragerWBeeEKHavermannIZschockeIOnset, longevity and subject satisfaction with incobotulinumtoxinA for the treatment of glabellar frown lines: a single-arm, prospective clinical studyClin Interv Aging2013
   Google Scholar
• DessyLAFallicoNMazzocchiMScuderiNBotulinum toxin for glabellar lines: a review of the efficacy and safety of currently available productsAm J Clin Dermatol201112637738821877763
   PubMed Web of Science ®Google Scholar
• JandhyalaRRelative potency of incobotulinumtoxinA vs onabotulinumtoxinA a meta-analysis of key evidenceJ Drugs Dermatol201211673173622648220
   PubMed Web of Science ®Google Scholar
• MarchettiAMagarRFindleyLRetrospective evaluation of the dose of Dysport and BOTOX in the management of cervical dystonia and blepharospasm: the REAL DOSE studyMov Disord200520893794415810022
   PubMed Web of Science ®Google Scholar
• KarsaiSRaulinCCurrent evidence on the unit equivalence of different botulinum neurotoxin A formulations and recommendations for clinical practice in dermatologyDermatol Surg20093511819018816
   PubMed Web of Science ®Google Scholar
• PragerWHuber-VorländerJTaufgAZBotulinum toxin type A treatment to the upper face: a retrospective analysis of daily practiceClin Cosmetic Invest Dermatol201255358
   Google Scholar
• BakshiEHartsteinMECompositional differences among commercially available botulinum toxin type ACurr Opin Ophthalmol201122540741221825992
   PubMed Web of Science ®Google Scholar